RituxiMab INDuction in Renal Transplantation

Inclusion Criteria: * Adult patients over 18 years receiving their first living donor renal transplant, or their second if the first was not lost from acute rejection * Patients who have given written informed consent * Women of child bearing potential taking adequate contraception. Exclusion Criteria: * Previous other organ transplants lost through acute rejection * Patients undergoing antibody incompatible transplantation * Patients with other organ transplants * Patients previously treated with cyclophosphamide, ATG, OKT3 or rituximab * Patients with white cell count below 4.0x10\^9/L. * Patients with platelet count below 100x10\^9/L * Patients who are treated with drugs that are strong inhibitors or inducers of cytochrome P450, or treated with terfenadine, astemizole, cisapride or lovastatin * Patients who have been involved in any other investigational trial or non protocol immunosuppressive regimen in the previous 90 days prior to transplant * Pregnant or breastfeeding women * Patients with a documented history of malignancy and its origins and treatment in the last five years. (Localised basal cell carcinoma of the skin is permitted) * Patients known to be HIV, Hepatitis B surface antigen or Hepatitis C antibody positive * Patients who in the opinion of the Investigator would not be a suitable candidate for study participation * Women of child bearing potential not willing to take adequate contraception